Craig Kevin James, serving as the Chief Medical Officer for AtaiBeckley Inc. (NASDAQ: ATAI), completed a significant transaction involving the sale of company equity on June 25, 2026. According to a recent SEC Form 4 filing, Mr. James sold 42,579 shares of the company's common stock. The total value realized from this divestment was $192,031. The transaction was executed at a weighted average price of $4.51 per share. Individual prices within this specific block ranged from $4.50 to $4.54 per share.
The structure of this sale is governed by a Rule 10b5-1 trading plan. Mr. James adopted this pre-arranged plan on December 19, 2025. This mechanism typically allows executives to trade shares during periods when they might otherwise be restricted by insider trading windows. The timing of the sale is notable given the recent performance of the stock. ATAI has experienced a substantial surge of 144% over the past year. At the time of the filing, the stock was trading at $5.36, which is above the $4.51 weighted average price at which Mr. James sold his shares. Market analysis indicates that ATAI may be overvalued at current levels, with the stock appearing in lists of significantly overvalued equities. The platform hosting this analysis offers additional ProTips and comprehensive financial metrics for deeper evaluation.
On the same date, June 25, 2026, Mr. James also engaged in the acquisition of shares through the exercise of stock options. Prior to the sale, he acquired 42,579 shares of AtaiBeckley common stock via this method. The total cost for these acquisitions was $60,819. The exercise prices varied for different portions of this block. Specifically, 33,051 shares were exercised at a price of $1.50 per share. An additional 9,528 shares were exercised at a lower price of $1.18 per share. These option exercises were also facilitated through the same Rule 10b5-1 trading plan established in December 2025.
Following these complex transactions, Mr. James's direct holdings in AtaiBeckley common stock totaled 8,437 shares. The stock options that were exercised under this plan had distinct vesting schedules. One option vesting schedule stipulated that 25% of its underlying shares vested on January 1, 2026. The remaining shares under this specific option vested in 36 substantially equal monthly installments thereafter. Another option followed a different timeline, with 25% of its underlying shares vesting on March 14, 2024, followed by similar monthly vesting schedules.
Concurrent with these executive transactions, AtaiBeckley has reported positive Phase 2a clinical data for its depression drug, BPL-003. The study, which was published in CNS Drugs, highlighted that a single intranasal dose of BPL-003 provided rapid antidepressant effects. This outcome was observed in patients with treatment-resistant depression who were already on stable SSRI therapy. The trial involved 12 adults diagnosed with moderate-to-severe major depressive disorder. These participants had not responded to at least two prior antidepressants.
Analyst sentiment surrounding AtaiBeckley has also shifted recently. Guggenheim has raised its price target for AtaiBeckley shares to $16. This upgrade cites that the company is now fully funded through pivotal readouts scheduled for early 2029. Canaccord has also increased its price target to $15. This firm aligned its pricing model for BPL-003 with similar treatments in the market. H.C. Wainwright reiterated a Buy rating with a $25 target. This action followed a recent investor discussion with AtaiBeckley's management. These developments reflect ongoing interest and confidence from analysts in AtaiBeckley's potential advancements.
The stock price data for ATAI shows a current value of 5.36, with a change of +0.070 or +1.32%. The market closed at 15:59:59 in USD. After hours trading at 18:17:57 showed a value of 5.360 with a 0.00% change. The chart data spans from 14:00 to 19:00, with prices ranging from 5.1 to 5.3. This data is generated using Highcharts 11.4.8.